JFGIW
DNLI icon

Johnson Financial Group Inc (Wisconsin)’s Denali Therapeutics DNLI Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Hold
81
– – ﹤0.01% 766
2026
Q1 		$1.56K Hold
81
– – ﹤0.01% 822
2025
Q4 		$1.34K Sell
81
-1,894
-96% -$32K ﹤0.01% 864
2025
Q3 		$28.7K Buy
+1,975
New +$28.4K ﹤0.01% 677

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s DNLI Position: Q2 2026 in Review

Johnson Financial Group Inc (Wisconsin) held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 81 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Johnson Financial Group Inc (Wisconsin) first reported a position in DNLI in Q3 2025 and has held it in 4 quarters since. The position peaked at $28.7K in Q3 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Johnson Financial Group Inc (Wisconsin) held 81 shares of Denali Therapeutics worth $2.08K as of Q2 2026.
  • Johnson Financial Group Inc (Wisconsin) left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Johnson Financial Group Inc (Wisconsin)'s portfolio in Q2 2026, its #766 holding.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in Denali Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Johnson Financial Group Inc (Wisconsin)'s Denali Therapeutics position peaked at $28.7K in Q3 2025.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q2 2026, filed 10 Aug 2026.